Bahl & Gaynor Inc. Sells 200 Shares of Gilead Sciences, Inc. $GILD

Bahl & Gaynor Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.5% in the first quarter, Holdings Channel reports. The institutional investor owned 2,154 shares of the biopharmaceutical company’s stock after selling 200 shares during the period. Bahl & Gaynor Inc.’s holdings in Gilead Sciences were worth $241,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in GILD. Price T Rowe Associates Inc. MD raised its holdings in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $620,415,000. GAMMA Investing LLC increased its position in shares of Gilead Sciences by 13,891.1% during the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock valued at $285,761,000 after purchasing an additional 2,532,070 shares during the period. Northern Trust Corp raised its stake in shares of Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after purchasing an additional 2,040,261 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the completion of the sale, the chief financial officer directly owned 160,110 shares in the company, valued at approximately $18,977,838.30. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the transaction, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at $69,016,306.50. This represents a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,000 shares of company stock valued at $9,339,230. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 1.2%

Shares of Gilead Sciences stock opened at $114.77 on Monday. Gilead Sciences, Inc. has a 12-month low of $75.91 and a 12-month high of $121.83. The stock has a market capitalization of $142.41 billion, a P/E ratio of 22.86, a price-to-earnings-growth ratio of 0.70 and a beta of 0.33. The company has a 50-day simple moving average of $112.51 and a 200 day simple moving average of $109.16. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences’s dividend payout ratio is 62.95%.

Wall Street Analyst Weigh In

GILD has been the topic of several analyst reports. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research report on Friday, July 25th. Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a research note on Friday, August 8th. Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.